预处理HIV耐药对含NNRTI方案疗效影响的系统综述与荟萃分析
结果显示,无论方案亚组、人群(儿童或成人)或耐药定义,有预处理耐药者病毒学失败风险均增高,获得新耐药突变和更换ART的风险也更高。结论支持世界卫生组织建议:在预处理耐药水平高的国家避免使用NNRTI。
要点
- 有预处理HIV耐药者启动含NNRTI方案后病毒学失败风险增高。
- 预处理耐药者获得新耐药突变和更换ART的风险也更高。
- 在预处理耐药水平高的国家应避免使用NNRTI。
核心结论
- 有预处理HIV耐药者启动含NNRTI方案的治疗结局更差,支持在预处理耐药水平高的国家避免使用NNRTI。
研究设计与样本
- 比较启动含NNRTI方案且有或无预处理耐药人群的治疗结局,并按方案、人群和耐药定义进行亚组分析。
主要发现
- 在所有亚组中,有预处理耐药者启动NNRTI方案后病毒学失败风险均高于无预处理耐药者。
- 有预处理耐药者获得新耐药突变的风险和更换ART的风险也更高。
临床怎么用
- 在预处理耐药水平高的国家,应避免使用含NNRTI的初始方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Increased access to antiretroviral therapy (ART) has resulted in rising levels of pretreatment human immunodeficiency virus drug resistance (PDR). This is the first systematic review and meta-analysis to assess the impact of PDR on treatment outcomes among people initiating nonnucleoside reverse transcriptase inhibitor (NNRTI)-based ART, including the combination of efavirenz (EFV), tenofovir (TDF), and lamivudine or emtricitabine (XTC). METHODS: We systematically reviewed studies and conference proceedings comparing treatment outcomes in populations initiating NNRTI-based ART with and without PDR. We conducted subgroup analyses by regimen: (1) NNRTIs + 2 nucleoside reverse transcriptase inhibitors (NRTIs), (2) EFV + 2 NRTIs, or (3) EFV/TDF/XTC; by population (children vs adults); and by definition of resistance (PDR vs NNRTI PDR). RESULTS: Among 6197 studies screened, 32 were analyzed (31 441 patients). We found that individuals with PDR initiating NNRTIs across all the subgroups had increased risk of virological failure compared to those without PDR. Risk of acquisition of new resistance mutations and ART switch was also higher in people with PDR. CONCLUSIONS: This review shows poorer treatment outcomes in the presence of PDR, supporting the World Health Organization's recommendation to avoid using NNRTIs in countries where levels of PDR are high.
引用
- Bertagnolio S, Hermans L, Jordan MR, et al. Clinical Impact of Pretreatment Human Immunodeficiency Virus Drug Resistance in People Initiating Nonnucleoside Reverse Transcriptase Inhibitor-Containing Antiretroviral Therapy: A Systematic Review and Meta-analysis. J Infect Dis. 2021. PMID: 33202025. doi:10.1093/infdis/jiaa683
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。